HD-OPM Archive
Hashtags

#pelacarsen

10 posts

Novartis Lp(a)HORIZON: pelacarsen failed to reduce heart attacks and strokes

Sep 04, 2026 · Louis Nervegna ♥ 20 · 💬 24 Lp(a)

Louis shares the first outcome-trial result for an Lp(a)-lowering drug: topline data from Novartis say pelacarsen lowered Lp(a) but did not show reduced cardiovascular risk overall. He says the result seriously questions whether Lp(a) is directly causal, noting only a press announcement is available so far.

Why lowering Lp(a) failed to cut heart attacks in the HORIZON trial, per Nature

Nov 03, 2026 · Louis Nervegna ♥ 10 · 💬 8 Lp(a)

Louis shares a Nature news feature asking why Lp(a) lowering did not reduce heart attacks and strokes in the HORIZON trial, with full results due November 7. The quoted passage explains that Lp(a) is like LDL but has an apolipoprotein(a) tail with kringle repeats, that particle for particle it carries about six times LDL's risk, and that clotting effects may matter.

Tsimikas on why Lp(a) HORIZON missed its endpoint despite strong Lp(a)-risk evidence

Sep 05, 2026 · Louis Nervegna ♥ 8 · 💬 6 Lp(a)

Louis shares a summary of Dr. Sam Tsimikas's comments on the pelacarsen HORIZON trial missing its primary endpoint. Evidence linking high Lp(a) to heart attack, stroke, PAD and aortic valve disease remains large, but most came from general populations before aggressive LDL lowering, and HORIZON patients were already aggressively treated.

Lp(a)HORIZON NEJM: pelacarsen cut Lp(a) 78% with no trend toward fewer events

Nov 07, 2026 · Louis Nervegna ♥ 6 · 💬 4 ↩ 1 Lp(a)

Louis summarizes the Lp(a)HORIZON paper in NEJM. Pelacarsen lowered Lp(a) by 78% but there was no reduction in MACE, not even a trend, with slightly more events on the drug (non-significant). Subgroups with Lp(a) above 90 mg/dL showed no extra benefit over 70-90, and serious adverse events were actually higher on placebo.

Tsimikas: Lp(a) risk can be managed with LDL under 65 and tight risk-factor control

Nov 10, 2026 · Louis Nervegna ♥ 13 · 💬 1 ↩ 1 Lp(a)

Louis quotes Sam Tsimikas, who calls Lp(a)HORIZON a success because it suggests Lp(a) risk can be reduced by keeping LDL-C at or below 65, blood pressure at 120 or lower, controlling other risk factors and taking proven medicines. In his Lp(a) clinic about 75% take a statin, 50% ezetimibe, 50% a PCSK9 inhibitor, plus aspirin.

Pelacarsen (Lp(a)HORIZON) and ziltivekimab (ZEUS) cut their targets but not heart events

Nov 13, 2026 · Louis Nervegna ♥ 3 · 💬 1 Lp(a)

Shared summary of two NEJM trials. Pelacarsen lowered Lp(a) sharply but event rates were 12.3% vs 12.1% on placebo, and ziltivekimab cut CRP and IL-6 but events were 17.6% vs 17.7%. The post notes prior biomarker failures (torcetrapib, dalcetrapib), and that both trials enrolled people with existing disease and so do not prove Lp(a) or inflammation are not causal.

Cleveland Clinic: pelacarsen did not cut CV events in Lp(a)HORIZON (12.3% vs 12.1%)

Nov 07, 2026 · Louis Nervegna ♥ 3 · 💬 1 Lp(a)

Louis shares the Cleveland Clinic press release on Lp(a)HORIZON, a 797-site randomized trial in 8,322 patients with prior CVD and Lp(a) of at least 70 mg/dL. The primary endpoint occurred in 12.3% on pelacarsen versus 12.1% on placebo after a median 57 months. Senior author Steven Nissen said a single neutral trial does not prove lack of benefit from lowering Lp(a).